课题基金 / 基金详情

Hereditary Genetics of Hepatocellular Carcinoma

Hereditary Genetics of Hepatocellular Carcinoma
肝细胞癌的遗传遗传学
批准号:
10366233
负责人:
Kirk J Wangensteen
金额:
$17.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-02-01 至 2022-06-30
关键词:
AddressAgeAge of OnsetAlcohol consumptionAlcoholsAnimal ModelBRCA2 geneCHEK2 geneCandidate Disease GeneChronicClinicalConfidence IntervalsDNA DamageDNA RepairDNA Repair GeneDefectDemographic FactorsDevelopmentDiagnosisEnrollmentEnvironmental Risk FactorExposure toFANCD2 proteinFamilyFamily Cancer HistoryFamily history ofFamily memberFanconi Anemia Complementation Group A ProteinFatty LiverFibrinogenFirst Degree RelativeGene ExpressionGenesGeneticGenetic ModelsGenetic Models for CancerGenetic studyHepatitis BHepatitis CHereditary Neoplastic SyndromesHistologicIndividualInheritedInstitutionInvestigationKnowledgeLinkLiver neoplasmsLoss of HeterozygosityMSH6 geneMalignant NeoplasmsMalignant neoplasm of liverMedical centerOdds RatioOutcomePMS2 genePathogenesisPathogenicityPatient CarePatientsPharmacotherapyPhenotypePilot ProjectsPlayPopulationPopulation ControlPractice GuidelinesPredispositionPrimary carcinoma of the liver cellsProteinsRecommendationRecording of previous eventsRiskRisk FactorsRoleStainsSusceptibility GeneTest ResultTestingToxic Environmental SubstancesTumor TissueVariantVirus Diseasesbasecancer cellcancer predispositioncancer riskcarcinogenesiscase controlclinical centerclinical practiceclinically relevantearly onsetexomefatty liver diseasegene functiongene panelgene repairgenetic associationgenetic panel testgenetic risk factorgenetic testinggenetic variantgenomic locushigh riskhomologous recombinationimprovedinhibitorinhibitor therapyinnovationliver cancer modelloss of functionmortalitypatient subsetspersonalized medicineprospectiverare variantrepairedresponsetargeted treatmenttreatment strategytumor

项目摘要

项目成果

Kirk J Wangensteen的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Hepatocellular Carcinoma (HCC) is a devastating and prevalent cancer of the liver with high rates of mortality. Major risk factors include chronic viral infection (hepatitis B or C), fatty liver disease, alcohol use, and exposure to environmental toxins. An independent risk factor is a family history of HCC, which raises the risk by more than 2.5-fold. However, despite evidence of familial risk, the inherited component remains unknown. It also remains unexplored whether inherited gene variants play a pathogenic role in HCC development, or whether they could be used to guide treatment with targeted therapies. We have pioneered an investigation into inherited (i.e. germline) genetic factors associated with HCC. We have completed a pilot analysis of 217 patients with HCC prospectively enrolled from our medical center for clinical-grade multigene panel genetic testing. We have captured details about their personal and family cancer history, risk factors, and outcomes. In our pilot analysis, we found a surprisingly high rate of pathogenic germline variants in cancer-associated genes in patients with HCC, including numerous pathogenic and likely pathogenic variants in genes required for homologous repair, DNA damage response (HR-DDR). We hypothesize that inherited loss-of-function variants in specific genes are enriched in HCC, and that carriers can be treated with targeted therapies. In Aim 1, we will conduct genetic association studies that are powered to detect clinically meaningful germline variants linked to HCC, and we will examine predictors of hereditary cancer syndromes in HCC including age of onset and family history of cancer. In Aim 2, we will explore the mechanism of HCC arising from defects in HR-DDR genes, and determine the implications for targeted therapies. These innovative studies of the hereditary genetics of HCC have the potential to personalize therapies for the subset of patients with hereditary cancer syndromes. We have assembled a team of experts in HCC, hereditary genetics, and animal models to complete this investigation. This study has the potential to impact on the care of patients with HCC in the US and worldwide.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hereditary Genetics of Hepatocellular Carcinoma
  • 批准号:
    10553668
  • 项目类别:
  • 资助金额:
    $61.0万
  • 财政年份:
    2022
  • 负责人:
    Kirk J Wangensteen
  • 依托单位:
Hereditary Genetics of Hepatocellular Carcinoma
  • 批准号:
    10632953
  • 项目类别:
  • 资助金额:
    $51.03万
  • 财政年份:
    2022
  • 负责人:
    Kirk J Wangensteen
  • 依托单位:
Hereditary Genetics of Hepatocellular Carcinoma
  • 批准号:
    10627405
  • 项目类别:
  • 资助金额:
    $20.0万
  • 财政年份:
    2022
  • 负责人:
    Kirk J Wangensteen
  • 依托单位:
Hereditary Genetics of Hepatocellular Carcinoma
  • 批准号:
    10598810
  • 项目类别:
  • 资助金额:
    $8.1万
  • 财政年份:
    2022
  • 负责人:
    Kirk J Wangensteen
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: